TVTX — Stock Analysis

FILSPARI is a generational drug launch hiding behind a binary catalyst. This company did 490.7MinFY25revenue(+11037.8M), achieved Non-GAAP profitability ($0.91 EPS), and is adding patients at an all-time high rate — all while trading at 5.3x run-rate P/S. The PEG of 0.048 is absurd. But the FSGS PDUFA on April 13 (11 days out) is the elephant in the room: the DUPLEX trial missed its primary eGFR endpoint, and the market is pricing that binary risk. I think the expected value is positive, but this is not a clean setup. Let me walk through the numbers.

Date: 2026-04-02 Market cap: ~2.76B(30.39 × 90.9M shares) FY ends: December (calendar year) Run-rate revenue: $518.8M (Q4 × 4) Run-rate P/S: 5.3x 52-week range: 12.91–42.13

The Numbers

Revenue Grid — Total ($M)

*Q3 FY25 inflated by $51.7M CSL Vifor license milestone. Net product sales were $113.2M.

→ Annual revenue growth is accelerating: 32.7% → 60.3% → 110.3%. This is a drug-launch S-curve, and it's textbook beautiful at scale.

FILSPARI Revenue Grid — The Only Number That Matters ($M)

FILSPARI quarterly YoY: Q1 +182% → Q2 +165% → Q3 +155% → Q4 +108%. Decelerating on base effects — expected and not a red flag when the annual number is +144%.

FILSPARI QoQ — Where I'm Watching Closely

QoQ has clearly stepped down from Year 1 post-launch (37/31/39%) to Year 2 (13/29/26/14%). 1 percentage point matters — 14% QoQ annualises to 69%, while Q4 FY24's 39% annualised to 275%. But this is normal drug launch dynamics: Year 1 captures pent-up demand, Year 2 runs on steady adoption.

What matters more is the dollar adds: FILSPARI added $12.4M in Q4 FY25 vs $14.0M in Q4 FY24. Dollar adds are stable despite a base that more than doubled. That's not deceleration — that's scale.

Net Product Sales — The Clean Growth Metric ($M)

License revenue is lumpy and non-recurring (CSL Vifor milestones). Strip it out. Product sales grew 81% YoY. FILSPARI is 78% of product sales and growing 144%. Tiopronin is a declining legacy product that will stabilise at ~$90M/year. Nuf said.

Profitability — The Inflection Is Real

The operating margin trajectory is staggering. From -336% in Q1 FY24 to +15.1% GAAP in Q3 FY25. Q4 stepped back to -25% due to (a) normalised license revenue after the Q3 CSL Vifor spike, and (b) SG&A ramp for FSGS launch prep.

Non-GAAP operating income turned positive in FY25 (+42.8M)vs−243M in FY24. That's a $286M swing in one year. This is a company that crossed the profitability Rubicon.

Annual OCF went from -325M(FY23) → −230M (FY24) → **+37.8M(FY25) * *.Firsteverpositiveoperatingcashflow.FCFstillslightlynegative(−20.4M) due to $58.2M in capitalised royalty/intangible investments — not operational burn.

Balance Sheet & Dilution

Net cash positive for the first time. Convertible debt reduced by $67M. Dilution in FY25 was only +1.9M shares (+2.1%) — a massive improvement from +12.5M shares in FY23. The equity-raise-to-survive phase is over. SBC was $44.9M (9.1% of revenue), down from 15.8% in FY24. Both trending in the right direction.

The A/R jump (+195% vs +73% revenue growth) is worth monitoring. Could be payer mix shift to institutional accounts (Medicaid carries longer payable cycles) or simply a timing lag from the Q4 FILSPARI volume surge. Not a red flag yet, but it's on my watch list.

Leading Indicators

PSF Count — The Alpha Signal

908 new Patient Start Forms in Q4 = all-time high. PSFs are the pharmaceutical equivalent of net new customer adds. Each PSF represents a doctor writing a FILSPARI prescription for a new patient. PSFs convert to filled prescriptions over weeks-to-months, making this a leading indicator of Q1 FY26 revenue.

The Q3 → Q4 re-acceleration from 731 to 908 kills any narrative about demand fatigue. This is a drug that is still in the steep part of its adoption curve.

Leading Indicator Divergence

No bearish divergence. All leading indicators are accelerating faster than consolidated revenue. This is the textbook pattern that precedes sustained growth.

The FSGS PDUFA — The Binary Event (April 13, 2026)

This is where I diverge from Atlas's assessment. Atlas gives conviction 4/5 and frames this somewhat as asymmetric upside. I think the FSGS risk is more nuanced — here's why:

What the DUPLEX Trial Actually Showed

The Phase 3 DUPLEX study in FSGS had two endpoints:

1. Primary endpoint (eGFR slope at 108 weeks): MISSED. No significant between-group difference vs irbesartan (0.3 ml/min/1.73m²/year, 95% CI -1.7 to 2.4).
2. Surrogate endpoint (proteinuria remission at 36 weeks): HIT. 64.7% partial remission vs 43.9% irbesartan. Statistically significant.

→ The FDA is reviewing an sNDA where the drug missed the hard clinical endpoint and hit only the surrogate marker. This is not a slam dunk.

Bullish Signals

• AdCom removed — FDA doesn't feel the need for external committee input. This is historically a positive signal (AdComs are called when the FDA is uncertain).
• Unmet medical need — FSGS has zero approved therapies. The bar for "first and only" is lower.
• PARASOL framework — Nephrology workgroup validated proteinuria reduction as a meaningful FSGS endpoint.
• Post-hoc data — Lower rates of end-stage kidney disease and higher rates of complete remission vs irbesartan at 108 weeks.
• Established safety — FILSPARI already approved for IgAN; the safety profile is known.

Bearish Signals

• Missed primary endpoint — The FDA's standard is eGFR for kidney drugs. Approving on proteinuria alone would be precedent-setting for FSGS.
• Major Amendment extension — The 3-month PDUFA extension signals the FDA wanted more data. Travere submitted additional analyses. The question is whether the additional data persuaded them.
• Active comparator design — Comparing to irbesartan (a standard-of-care ARB) means the delta is smaller. The drug might work, but proving it works better than existing therapy is harder when the primary endpoint misses.

My Probability Estimate: ~60-65% Approval

Higher than a coin flip because of AdCom removal and unmet need, but lower than the market seems to be pricing based on the stock's recent move from ~$28 to $30+. The missed eGFR endpoint is a genuine FDA review concern that most bull analyses downplay.

Scenario Matrix

→ Positive expected value, but not by a wide margin. The expected return of ~12% is thin for a position with 35% downside risk.

Competitive Landscape

The IgAN market has gone from zero approved therapies to four in less than three years. This is early innings of a $730M+ market growing at 30% CAGR.

Key insight: Novartis is throwing three drugs at IgAN. That's both a threat (commercial firepower) and a validation (the market is real and growing). FILSPARI's differentiators are: (a) KDIGO first-line endorsement (Sept 2025), (b) dual mechanism, (c) proven eGFR benefit vs active comparator in PROTECT trial (31% complete remission vs 11%), (d) REMS simplified to quarterly monitoring (Aug 2025).

Interesting data point: Novartis's Vanrafia (atrasentan) ALIGN trial showed eGFR benefit at p=0.057 — borderline miss of statistical significance. So Novartis's drug also has endpoint questions. This is a drug class where proving hard endpoints takes long trials with large patient numbers.

The market will expand faster than any single drug loses share. This is the immune-oncology playbook: 4+ drugs, growing total market, different mechanisms for different patients. FILSPARI's share may compress from ~44% but absolute revenue will keep growing.

Valuation

The PEG of 0.048 is the cheapest I've seen for a company growing >100% YoY with positive OCF. Mid-cap biotech peers growing 20-40% trade at 4-6x P/S. TVTX is growing 110% at 5.3x. The market is pricing in either FSGS rejection, severe competitive erosion, or both.

Rule of 40 at 117% is exceptional. This puts TVTX in the top decile of growth companies across all sectors — not just pharma. Revenue growth of 110% plus 7.7% OCF margin means this is a company growing explosively AND generating cash.

Q4 run-rate Non-GAAP P/E of 20.7x is arguably cheap for a company growing this fast. If FILSPARI grows mid-20% in FY26 (management's "meaningful growth" guidance) and FSGS adds even modest revenue, FY26 Non-GAAP EPS could reach $1.50-2.00. At $30/share, that's 15-20x forward P/E on a company growing 50%+.

FY26 Revenue Bridge (My Estimates)

→ Without FSGS, FY26 growth decelerates sharply to single-digits as the license milestone comp ($80M in FY25) rolls off. On product sales alone, growth would be ~25-30%. This is why FSGS matters so much — it's not just incremental, it determines whether the revenue growth narrative stays intact.

Management Assessment

• Eric Dube (CEO): Joined 2020 from Pfizer. Led FILSPARI through launch, REMS simplification, KDIGO endorsement, and profitability inflection. Strong execution track record. Conservative guidance ("meaningful growth" with no dollar target) — which I like. Underpromise culture.
• No quantitative guidance provided — management doesn't give quarterly or annual dollar targets. This makes beat/miss tracking impossible but signals confidence that they don't need to manage expectations with precise numbers.
• SG&A spending is aggressive: 101.7MinQ4(+4615-20M/quarter in excess spend that needs to be unwound. A management quality test.
• Revenue per employee: ~$1.1M on ~385 employees. Exceptionally lean for commercial pharma.
• Analyst consensus: 8 Buy, 2 Hold, 0 Sell. Average PT $42 (38% upside from current).

Where I Differ From Atlas

Atlas scores conviction 4/5 and presents the FSGS catalyst as mostly asymmetric upside. I see three gaps:

1. The DUPLEX eGFR miss is underweighted. The primary endpoint was not met. Period. Proteinuria is a surrogate. The FDA approving on surrogate alone in a disease with no precedent for this is uncertain. Atlas mentions this but doesn't change the conviction score. I'd score conviction 3/5 — strong company, uncertain near-term catalyst.

2. FY26 growth deceleration without FSGS is severe. Total revenue could decelerate from 110% to single-digits due to the $80M license comp rolling off. Product sales would grow ~25-30%, which is respectable but not hypergrowth. The thesis shifts from "explosive growth" to "solid specialty pharma" without FSGS.

3. SG&A pre-spend for FSGS is a double-edged sword. The $100M+/quarter SG&A run-rate is 46% higher than a year ago. If FSGS is rejected, this spend doesn't vanish overnight. Q1-Q2 FY26 margins could be ugly.

Thesis

TVTX is a rare inflection story — a specialty pharma transitioning from chronic cash-burner to profitable growth compounder — at a valuation that prices in meaningful downside risk. FILSPARI's launch trajectory is exceptional: 908 PSFs (ATH), 144% FY25 growth, KDIGO first-line endorsement, REMS simplified. The company achieved its first positive OCF year and turned Non-GAAP profitable. Dilution has slowed to 2%. The balance sheet is net cash positive for the first time.

The thesis rests on two pillars:

1. FILSPARI's IgAN franchise is durable and undervalued. Even without FSGS, the IgAN market is $730M+ and growing 30% CAGR. FILSPARI has dual mechanism, proven eGFR benefit, and KDIGO endorsement — real moats. Competitive intensification from Novartis is manageable because the market expands faster than any single drug loses share.
2. FSGS is the call option, not the core thesis. If approved (60-65% probability), it roughly doubles the addressable market and re-rates the stock to $4-5B. If rejected, the IgAN franchise alone supports $2.0-2.3B market cap — meaning downside from current is ~20-25%.

Risk factors in order of severity:

1. FSGS PDUFA rejection (April 13) — missed primary eGFR endpoint creates real uncertainty
2. GTN headwind (mid-20% vs ~20%) compresses ~$20-25M of net revenue
3. Competitive erosion from Novartis's three IgAN drugs
4. SG&A discipline if FSGS is rejected
5. Convertible debt terms unknown ($311.7M outstanding)

Action

I haven't written about TVTX before, but applying my framework: this is a Watchlist-with-intent position. The numbers are compelling — 110% growth, 98% gross margins, positive OCF, PEG 0.048, Rule of 40 at 117%. Green flags everywhere. But I don't take large positions into binary regulatory events where the drug missed its primary endpoint. That's gambling, not investing.

My plan:

• Pre-PDUFA (now): Small starter position (2-3%) if below $30. The expected value is positive.
• Post-PDUFA if approved: Add aggressively to 5-7%. The competitive moat + FSGS + IgAN makes this a multi-year compounder.
• Post-PDUFA if rejected: Evaluate at the bottom (~$20-22). If the IgAN franchise is intact and PSFs are still growing, buy the dip. The IgAN-only thesis is worth $2.0-2.3B and the stock would likely overshoot to the downside.

→ Conviction: 3/5 (held back by binary event uncertainty) → Rating: BUY on dip / ADD post-FSGS approval

-wsm

(No position in TVTX. First coverage.)

Sources

• Scout brief: 2026-04-01 (16 quarters EDGAR + Q4 FY25 BusinessWire PR)
• Atlas baseline: 2026-04-01 stock analysis
• NEJM DUPLEX Trial Results — Primary eGFR endpoint missed, proteinuria surrogate hit
• Travere IR: FDA Extends FSGS Review — PDUFA extended to April 13, 2026 (Major Amendment)
• Seeking Alpha: No AdCom, No Problem — AdCom removal analysis
• ISN: DUPLEX Trial Analysis — "Sparsentan decreased proteinuria but failed to slow eGFR decline"
• HCPLive: IgAN 2025 Year in Review — Competitive landscape
• HCPLive: Sparsentan Kidney Failure Risk — Post-hoc DUPLEX benefit data
• DelveInsight: IgAN Market — $878M market (2025), 30.5% CAGR
• TipRanks: TVTX Forecast — 8 Buy / 2 Hold, avg PT $42